Celgene and Novartis filed suit against Teva Pharmaceuticals over six patents related to phenidate drug formulations with diminished abuse potential. 12/2, District of New Jersey, 2:2011cv07064.
Access to the full article is currently available to RPX members only. Please contact us if you need further information.
